{"id":14803,"date":"2019-12-20T06:27:37","date_gmt":"2019-12-20T11:27:37","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14803"},"modified":"2019-12-20T06:27:37","modified_gmt":"2019-12-20T11:27:37","slug":"aducanumab-isnt-the-simple-solution-to-the-complicated-alzheimers-crisis","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14803","title":{"rendered":"Aducanumab isn\u2019t the simple solution to the complicated Alzheimer\u2019s crisis"},"content":{"rendered":"<p>(By Jason Karlawish for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">T<\/span><\/span>his year\u2019s Clinical Trials on Alzheimer\u2019s Disease meeting began in mid-December with a bang and ended a few days later with hallway conversations laced with worry. The topic, in both cases, was aducanumab, an experimental drug for treating people with Alzheimer\u2019s disease.\u00a0 Continue reading article <a href=\"https:\/\/www.statnews.com\/2019\/12\/20\/aducanumab-isnt-simple-solution-complicated-alzheimers-crisis\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Jason Karlawish for STAT) This year\u2019s Clinical Trials on Alzheimer\u2019s Disease meeting began in mid-December with a bang and<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,15],"tags":[],"class_list":["post-14803","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14803"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14803\/revisions"}],"predecessor-version":[{"id":14804,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14803\/revisions\/14804"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}